Skip to main content
    S

    Stoke Therapeutics Inc (STOK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $26.63
    -0.05 (-0.19%)

    Market Cap: $1.75B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Stoke Therapeutics Inc (STOK) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Stoke Therapeutics (STOK) trades at 64.5x sales and 5.2x book value. Its P/S of 64.5x is above its 5-year median of 31.6x. Its forward P/E is 204.1x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E204.1x
    Price to sales64.5x
    Price to book5.2x
    PEGN/A
    FCF yield-11.8%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S64.5x31.6xN/A
    P/B5.2x2.9xN/A
    Medians of month-end values through Oct 2026: 56 to 60 months (5-year).

    Valuation History

    Over the 4 of the 7 year ends shown that have a P/S, its P/S ranged from 10.0x in 2025 to 28.9x in 2022. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$31.7410.0x5.3x
    2024$11.0316.7x2.7x
    2023$5.2626.0x1.5x
    2022$9.2328.9x2.0x
    2021$23.99N/A4.1x
    2020$61.93N/A7.6x
    2019$28.32N/A3.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About STOK

    What is STOK's forward P/E ratio?

    Stoke Therapeutics has a forward P/E ratio of 204.1x.

    Is STOK stock overvalued?

    GNG's valuation label for STOK is Overvalued.

    What is STOK's price to sales ratio?

    Stoke Therapeutics has a price to sales ratio of 64.5x.